top of page
Pipetting Samples

"Dual acting cancer therapeutics targeting
solid tumors"

About SOLID

SOLID Therapeutics is an early-stage oncology company which is based on research at University of Copenhagen joining expertise in metabolite GPCR structure-based drug discovery in the Schwartz-Frimurer labs at the Novo Nordisk Foundation (NNF) Center for Basic Metabolic Research (CBMR) with the deep insight into cell biology of the tumor microenvironment in the Falsig Petersen lab. The concept of HCAR1 antagonists as anti-cancer drugs was supported by an Exploratory Pre-Seed grant from NNF, a Pre-Seed grant from the Bioinnovation Institute (BII) and an Innobooster grant from Innovationsfonden. The company was officially founded in March 2022 when accepted into the Venture Lab at BII.

BioInnovation Institute
BioInnovation Institute

press to zoom
SOLID Therapeutics
SOLID Therapeutics

press to zoom
BioInnovation Institute
BioInnovation Institute

press to zoom
1/2
m4+MC38_edited.jpg

"WE AIM TO DELIVER NOVEL CANCER THERAPEUTICS
WITH DUAL MODE OF ACTION TARGETING
BOTH CANCER CELLS AND IMMUNE CELLS"

ONE target - TWO mechanisms

Webpage - Cancer cell - Dendritic cell - T cell (2).png

A hallmark of solid tumors is the hypoxic and acidic microenvironment rich in lactate, which today is known to act as a signaling molecule sensed by the HCAR1/GPR81 receptor. HCAR1 expression is normally highly tissue restricted but is strongly induced by the tumor microenvironment in basically all types of solid tumors including hard-to-treat cancers. Importantly, high HCAR1 expression is associated with poor survival in e.g., breast and pancreatic cancer patients.

 

HCAR1 is expressed both on cancer cells and anti-cancer immune cells. HCAR1 improves survival of cancer cells by reprogramming their metabolism and upregulating defense mechanisms such as angiogenesis and check-point ligands. Importantly, HCAR1 is also involved directly in immune evasion by decreasing immune cell activation.

 

HCAR1 antagonists will therefore attack solid tumors in two ways by both directly impairing cancer cell survival and by stimulating tumor immunity.

Lundø et al. Cell Metabol. (2020) 31(4):666-668.

Figure created with BioRender.com

News

Mette_Trauelsen.jpg

November 2022

Mette Trauelsen appointed CEO of SOLID Therapeutics

Before being appointed as CEO of SOLID Tx, Mette Trauelsen was postdoc at CBMR/UCPH and head of Pharmacology and Cancer Biology at SOLID Tx. Here she established the in vitro assays and spearheaded the development of the in vivo efficacy cancer models.

Innovationsfonden.png

September 2022

SOLID Therapeutics receives an Innobooster grant from Innovation Fund Denmark

To expand the preclinical development package, the company receives an Innobooster grant of 1.2 M DKK from Innovation Fund Denmark (under the initial company name Warburg Oncology).

_DSF5725.jpg

March 2022

SOLID Therapeutics accepted into BII Venture Lab

The company receives a convertible loan of 0.5 M EUR from BII and is accepted into the BII Venture Lab (under the initial company name Warburg Oncology).

Contact Us

Contact

+45 27396775

  • LinkedIn

Address

Ole Maaløes Vej 3, 1 floor
DK 2200 Copenhagen N
Denmark

bottom of page